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Abstract
Aims The current article provides a brief overview of the
criteria for defining disease control in acromegaly.
Methods This was a retrospective, narrative review of
previously published evidence chosen at the author’s dis-
cretion along with an illustrative case study from Latin
America.
Findings and Conclusions In the strictest sense, ‘‘cure’’
in acromegaly is defined as complete restoration of normal
pulsatile growth hormone secretion, although this is rarely
achieved. Rather than ‘‘cure’’, as such, it is more appro-
priate to refer to disease control and remission, which is
defined mainly in terms of specific biochemical targets (for
growth hormone and insulin-like growth factor-1) that
predict or correlate with symptoms, comorbidities and
mortality. However, optimal management of acromegaly
goes beyond biochemical control to include control of
tumour growth (which may be independent of biochemical
control) and comprehensive management of the symptoms
and comorbidities typically associated with the disease, as
these may not be adequately managed with acromegaly-
specific therapy alone.
Keywords Acromegaly  Pituitary  Latin America 
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Introduction
Acromegaly is a disease of excessive growth hormone
(GH) secretion and the primary aims of treatment are to
control GH secretion or its effects on GH-sensitive tissues,
most notably increased insulin-like growth factor-1 (IGF-1)
secretion [1]. Intrinsically, ‘‘cure’’ in acromegaly should be
characterized by complete restoration of normal pulsatile
GH secretion, but this is rarely achieved [2]. Thus, it is
more appropriate to refer to disease control and remission,
which in turn is defined based on specific GH and IGF-1
targets that predict or correlate with symptoms, co-mor-
bidities and mortality [3]. Tumour mass reduction or dis-
appearance is also used in establishing disease remission or
control [3]. In surgically treated patients, remission is
defined by both the normalization of age-adjusted IGF-1
serum concentrations, a random serum GH below 1 lg/L
and/or a glucose-suppressed GH level below 0.4 lg/L. In
patients treated with SSAs and/or dopamine agonists,
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adequate control is defined by the achievement of a normal
IGF-1 concentration and a ‘‘safe’’ GH level (see below). In
this context, a ‘‘safe’’ GH level alludes to a concentration
of the hormone below which the increased mortality is
reduced to that seen in the general population [3–6].
However, optimal management of patients with acromeg-
aly extends beyond biochemical control to include factors
such as tumor growth and attention to comorbid conditions.
The current article summarizes the criteria for defining
disease control in acromegaly, with an illustrative case
study and a particular focus on issues in Latin America.
Measurement of GH and IGF-1 in acromegaly
Assays for GH and IGF-1 have evolved considerably over
the past two decades, from the less specific and sensitive
radioimmunoassays (RIAs), to a myriad of commercially
available ultrasensitive immunoassays that use more spe-
cific monoclonal antibodies, which are capable of detecting
much lower hormone concentrations [7, 8]. Several ana-
lytical and physiological issues need to be taken into
account when using GH and IGF-1 assays in the diagnosis
and follow-up of patients with acromegaly. This includes
the standard preparation used (the so-called International
Reference Preparation or ‘‘IRP’’), which at present should
be the recombinant World Health Organization (WHO)
second 95/574 preparation for GH and the recombinant
WHO second 02/254 preparation for IGF-1 [7–10]. Other
analytical aspects to be considered are the specificities of
the monoclonal antibodies and, in the case of IGF-1, the
interference from IGF-1-binding proteins [9].
Several physiological and pathological states or condi-
tions influence GH and IGF-1 synthesis and secretion. For
instance, GH is secreted in pulses occurring mainly at
night; thus, a random measurement is not useful, except
when the result is particularly low (less than 0.4 lg/L),
which confidently excludes the diagnosis [3]. Furthermore,
IGF-1 concentrations decrease with age, reflecting the
parallel decline of the somatotropic axis, and thus need to
be adjusted accordingly. Ethnogenetic factors may also
influence IGF-1 levels and, ideally, normal ranges should
be established locally using serum from a significant
number of age-stratified healthy individuals [9, 11]. In
addition, several conditions can lower IGF-1 levels,
including malnutrition, poorly controlled diabetes, and
hepatic or renal failure, as well as estrogen therapy and
hypothyroidism [9, 11].
Biochemical versus symptom control
Based on meta-analyses, mortality of treated acromegaly
patients whose serum GH level is below 2.5 lg/L (mea-
sured by RIA) is similar to that seen in the general popu-
lation [12, 13]. In contrast, a serum GH level greater than
2.5 lg/L confers an increased risk of mortality [12, 13]. A
similar pattern is seen for IGF-1 when comparing normal
Fig. 1 MRI scans of pituitary tumor at diagnosis (April 2008, left) and following non-curative surgery (January 2009, right) prior to
commencing pharmacological therapy
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age-adjusted levels versus levels above the age-adjusted
normal range [12, 13]. Based on these observations, clini-
cians treating acromegalic patients are advised to aim for
random serum GH \2.5 lg/L measured by RIA (probably
\1 lg/L measured by modern sensitive immunoassay) and
normal IGF-1 levels, and this represents the current defi-
nition of controlled disease or ‘‘cure’’ [2, 3, 12, 13].
Unfortunately, there are patients who meet the above
criteria for GH who are still symptomatic, have clear evi-
dence of progression of co-morbidities or who have
abnormally elevated IGF-1 [2, 14]. Thus, measured values
of IGF-1 and random GH may yield a discrepant prediction
of disease stabilization, especially in terms of symptomatic
disease [2, 14]. In these cases, the IGF-1 level may provide
a better measure of average GH secretion, as it correlates
well with signs and symptoms of active disease, such as
soft-tissue thickening and insulin insensitivity [2, 14, 15].
Furthermore, IGF-1 seems to be a better predictor of dis-
ease control than random GH [2, 15]. Although cumber-
some and less practical, whenever random GH values are
discrepant, multiple GH sampling during a 2-h period with
a mean value \1 lg/L may be used to indicate adequate
disease control [16].
Suppression of GH during an oral glucose tolerance test
(OGTT) is of limited value in evaluating disease control in
many patients, being helpful only in those who are not
receiving any pharmacological treatment, most notably in
the postoperative setting [2, 3, 16, 17]. Some evidence also
suggests that radiotherapy can exaggerate the discordance
between disease activity assessed by IGF-1 and GH sup-
pression during an OGTT (if GH nadir is\2.5 lg/L) [18]. In
treatment-naı¨ve, biochemically active patients, discordance
appears to be greatest in those with only mildly elevated GH
output, leading to a high false negative rate with GH sup-
pression measurement [19]. Increased discordance is also
seen at the other extreme in patients with particularly high
GH levels [20]. In patients treated with pegvisomant, only
IGF-1 remains a reliable marker of disease activity, as GH
concentrations remain elevated [3, 16].
Thus, for patients receiving medical treatment with
SSAs or dopamine agonists, IGF-1 and random GH mea-
surements together are sufficient for assessment of bio-
chemical response [2, 3]. The IGF-1 level, in particular,
can be an important determinant of the need for additional
therapy, although results can be influenced by the presence
of malnutrition, poorly controlled diabetes mellitus, hypo-
thyroidism, liver function impairment, renal failure,
inflammatory diseases and malignancies [9, 11, 21].
Finally, it should be noted that the effects of pharmaco-
logical therapies on tumor size may not necessarily be
related to biochemical remission, and this may represent an
aspect of disease control that deserves separate consider-
ation [3, 22–24].
Tumor shrinkage
Tumor size reduction is an important goal in the manage-
ment of acromegaly [3, 6]. In the first-line clinical setting,
control of both GH secretory activity and tumor growth are
required in order to achieve comprehensive therapeutic
efficacy [3, 6]. The clinical relevance of tumor shrinkage
may be greater in macroadenomas than in microadenomas
[24]. The clinical benefits of tumor mass shrinkage include
relief of optic chiasm impingement, patient reassurance
that the mass is shrinking, and possibly a lowered risk of
intratumoral hemorrhage [25]. Such effects have the
potential to provide a noticeable beneficial impact on
patient quality of life.
In addition to the achievement of biochemical control,
some pharmacological therapies can also induce significant
tumor shrinkage in patients with acromegaly [24–28].
Tumor shrinkage has been reported in approximately two-
thirds of patients treated with long-acting SSAs and one-
third of patients treated with dopamine agonists [24, 28]. The
SSAs being used today are almost exclusively longer-acting,
depot formulations and they seem to provide more benefit in
reducing tumor size than the old shorter-acting formulations
[24, 29]. The effects on tumor size are especially marked
when these agents are used as first-line therapy [29]. In a
recent study involving 30 newly diagnosed unselected
patients receiving SSA therapy for 24 weeks, 97 % experi-
enced a reduction in tumor volume, 79 % had a reduction
C20 % and the median reduction in volume was 39 % [30].
In the case of SSAs, the anti-tumor effects may relate, at least
in part, to direct effects on cell growth and indirect effects via
inhibition of angiogenesis [27]. The available evidence
suggests that pegvisomant does not reduce tumor size, at
least when used as monotherapy [31]. Earlier concerns
regarding pituitary adenoma growth during pegvisomant
therapy now seem to have settled to an estimated risk of
about 3 % thanks to long-term follow-up studies [32].
Control of comorbidities
Major comorbidities associated with acromegaly include
cardiovascular disease (including cardiomyopathy), diabe-
tes, hypertension, sleep apnea, and arthritis [3, 33–36].
Acromegaly is also associated with a greater risk of several
neoplasms, particularly colonic polyps and carcinoma, and
there is growing evidence that the risk of thyroid tumors is
also increased [33, 37–40]. Furthermore, in addition to
hypertension and diabetes, active acromegaly is associated
with several other classic and nonclassic cardiovascular
risk factors, including insulin resistance and dyslipidemia,
as well as increased levels of fibrinogen and lipoprotein
(a) [41].
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Biochemical control has been shown to provide
improvements in several comorbidities of acromegaly,
especially cardiomyopathy, sleep apnea, and arthralgia, but
also hypertension and dyslipidemia [3, 42, 43]. In one study
involving 30 patients with newly diagnosed acromegaly,
12 months of SSA therapy decreased joint thickness in all
cases, but the reduction was greater in those with controlled
disease, among whom 61 % had normalization of shoulder
thickening and 89 % had normalization of knee thickening
[33]. Similarly, successful biochemical control after
12 months of SSA therapy has been shown to normalize left
ventricular (LV) hypertrophy in 100 % and LV ejection
fraction in 80 % of patients under 40 years of age (but only
50 % of patients over 40 years of age for either measure)
[33]. These results are supported by a meta-analysis of 18
SSA trials, which found a significant reduction in LV mass
and several functional hemodynamic parameters [44]. In a
recent study, LV mass regression was reported in men (but
not women) and there were also significant improvements
in arterial stiffness and endothelial function after 24 weeks
of SSA therapy [30]. In the same study, 61 % of the 30
patients exhibited an improvement in sleep apnea, but 30 %
experienced worsening and 9 % had no change [30]. Thus,
effective biochemical control does not always result in
effective control of these comorbidities and improvements
may be limited, in spite of normalized GH levels [3, 41, 42,
45]. Additional therapies are, therefore, frequently required
to treat comorbid conditions in acromegaly. In particular,
effective control of diabetes, hypertension and dyslipidemia
is essential in order to reduce the increased vascular mor-
bidity and mortality associated with these key cardiovas-
cular risk factors [3, 42]. Fortunately, good glycemic
control can be achieved in the majority of acromegalic
patients with type 2 diabetes using standard approaches,
such as lifestyle intervention, oral glucose-lowering agents
and insulin [46]. Hypertension in acromegaly is also easily
controlled with standard antihypertensive medications [47].
Regarding dyslipidemia, statin therapy has been shown to
provide significant improvements in atherogenic lipid pro-
file and reduce calculated coronary heart disease risk in
patients with acromegaly [48].
Case study: Addressing multiple comorbidities in a patient with
acromegaly (Lucio Vilar, MD, PhD)
A 40 year-old female was referred to the endocrinologist in April
2008 due to amenorrhea over the previous 10 months
Symptoms
Increased shoe size (from 35 to 38)








Blood Pressure (BP): 160/100 mmHg




Personal and family history
No family history of diabetes, cancer, thyroid disease or pituitary
disease
The last medical evaluation was made in 2004; no biochemical
abnormality was found
Lab tests
GH (ICMA): 23.8 lg/L
IGF-1 (ICMA): 960 lg/L (normal 101–267 lg/L)
GH nadir during OGTT: 6.3 lg/L
Prolactin and thyroid function tests: normal
Estradiol: 46 pmol/L (12.6 pg/mL)
FSH: 0.8 IU/L
Fasting plasma glucose: 7.6 mmol/L (137 mg/dL)
HbA1c = 7.4 %
Serum calcium: normal
Triglycerides: 5.5 mmol/L (487 mg/dL)
HDL cholesterol: 0.8 mmol/L (31 mg/dL)
Diagnosis
Acromegaly caused by a GH-secreting pituitary macroadenoma
MRI
Macroadenoma (2.3 9 1.8 cm), with infrasellar, parasellar and
suprasellar extension (Fig. 1)
Computerized visual field testing ) Normal
Echocardiogram
Marked left ventricular (LV) hypertrophy
No valvular abnormalities
Treatment
Patient was submitted to transsphenoidal surgery in Sept 2008,
which was not curative (Fig. 1)
IGF-1: 802 lg/L (normal 101–267 lg/L)
GH: 13.6 lg/L
GH nadir: 3.7 lg/L
SSA was started in March 2009, followed by a higher dose in
May 2009 followed by SSA ? cabergoline 3 mg/week
IGF-1 response to medical treatment showed improvement to
normal range (101–267 lg/L) with sequential medical therapy
from 780 lg/L to 253 lg/L
Thyroid ultrasound
June 2008: normal
January 2011: 1.7 cm hypoechoic solid nodule with increased
blood flow in right lobe
FNA biopsy ) Papillary thyroid carcinoma
March 2011 ) Total thyroidectomy
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Case discussion
This case provides a good example of a patient with a
burden of multiple comorbidities typical of acromegaly,
including diabetes, dyslipidemia and hypertension (all of
which are major cardiovascular risk factors), cardiomyop-
athy, arthralgia, and sleep apnea, along with thyroid car-
cinoma. After surgical failure, biochemical control and
tumor shrinkage was achieved through the use of phar-
macological therapy, which was ultimately successful
using a combination of SSA and dopamine agonist [49,
50]. Biochemical control was associated with improve-
ments in some comorbid conditions (e.g., excessive snor-
ing/sleep apnea) and may have contributed to amelioration
of dyslipidemia and cardiomyopathy. However, appropri-
ate specific therapies for diabetes (metformin), hyperten-
sion (losartan/amlodipine/indapamide) and thyroid
carcinoma (thyroidectomy/131I therapy) were required to
provide complete management of acromegaly and its
comorbidities. At present, blood pressure and diabetes
remain well controlled and the patient has not had recur-
rence of thyroid carcinoma.
Conclusions
If managed appropriately, most patients with acromegaly
should be able to achieve disease control without excess
morbidity or mortality, although success may be limited by
the modes of treatment and specific drugs available to the
treating physicians [3]. The main criteria for ‘‘disease
control’’ (rather than the more impracticable concept of
‘‘cure’’) involve achievement of pre-defined targets for GH
and IGF-1. These are based on the levels of GH and IGF-1
that have been shown to be associated with improved
symptoms and reduced frequency and severity of comorbid
conditions, as well as mortality levels approaching those of
the general population [3, 6]. However, beyond these bio-
chemical targets, other factors are also important goals in
the management of patients with acromegaly, such as
reduction in tumor size (which can be achieved in the
majority of patients receiving long-acting SSAs and, to a
lesser extent, with dopamine agonists), and more targeted
control of comorbid conditions [3, 6]. While some
comorbid conditions may be improved to a limited degree
with acromegaly-specific therapies alone, they often
require other more specific therapies for comorbidities,
including the use of antihypertensive, antihyperglycemic
and lipid-modifying drugs to control diabetes and reduce
the risk of cardiovascular disease. Thus, optimal manage-
ment of acromegaly encompasses biochemical control,
tumor growth control and comprehensive management of
the comorbidities commonly associated with acromegaly,
such as diabetes mellitus, hypertension and dyslipidemia,
which generally respond well to standard therapy .
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